3rd Annual Real World Evidence 360 Conference 2027

Attendees, exhibitors & solutions

Who this event is for

Industry trends

Key trends shaping this market and its wider industry.

Hotel tiers

A range of accommodation options near the venue and across key areas.

Local transport

Get around the city with these convenient transport options.

Frequently asked

Glossary

1

Real-world data (RWD)

Health-related data collected outside a conventional randomised controlled trial, such as electronic health records, insurance claims, patient registries, wearable devices and patient surveys.

2

Real-world evidence (RWE)

Clinical evidence about the use, benefits or risks of a health technology derived from analysis of real-world data.

3

Health technology assessment (HTA)

A systematic process used by payers and health systems to evaluate the safety, clinical effectiveness, cost-effectiveness and budget impact of medicines, devices and diagnostics.

4

Market access

The set of activities that determines whether patients can obtain a product at a reimbursed or affordable price, including pricing, reimbursement and payer engagement.

5

Payer

An organisation that funds or reimburses healthcare, such as a national health system, sickness fund, private insurer or employer plan.

6

Health economics and outcomes research (HEOR)

A discipline that evaluates the cost, value and patient outcomes of healthcare interventions using economic models, observational data and patient-reported measures.

7

Patient-reported outcome (PRO)

A measurement of a patient's health status, symptoms, function or quality of life reported directly by the patient rather than interpreted by a clinician.

8

Electronic health record (EHR)

A digital record of a patient's medical history, diagnoses, treatments, laboratory results and encounters maintained by a care provider.

9

Claims data

Billing and reimbursement records from insurers or health systems that show diagnoses, procedures, prescriptions and healthcare utilisation.

10

Patient registry

An organised system that collects standardised data on patients with a specific condition, treatment or exposure over time.

11

External control arm (ECA)

A comparison group assembled from historical trial data, registries or real-world datasets rather than from patients randomised in the current study.

12

Target trial emulation

A method that applies the design principles of a randomised trial to observational data in order to reduce bias and clarify causal questions.

13

Indirect treatment comparison (ITC)

A statistical method for comparing treatments that have not been studied head-to-head in a randomised trial, often using a common comparator.

14

Systematic literature review (SLR)

A structured and reproducible review that identifies, appraises and synthesises all relevant studies on a defined question.

15

Value dossier

A submission document that assembles clinical, economic and patient-relevant evidence to support reimbursement, formulary or HTA decisions.

16

Reimbursement

The process by which a payer agrees to pay for a medicine, device or service, often after HTA review and price negotiation.

17

Regulatory-grade RWE

Real-world evidence generated with sufficient data quality, methodological rigour and pre-specification to support regulatory decisions such as label changes or post-authorisation commitments.

18

Data linkage

The process of connecting records from different datasets, such as registries, EHRs and claims, to create a more complete patient-level view.

19

Decentralised or hybrid study

A clinical study design in which some or all activities, such as consent, data collection or follow-up, take place remotely or in participants' homes rather than only at a site.

20

Budget impact model

A health economic model that estimates the financial consequences of adopting a new technology for a payer's budget over a defined period.